You are here: Home » 2023 » August » Archives for 8th

EQUITY ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages KeyCorp Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – KEY

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of KeyCorp (NYSE: KEY) between February 27, 2020 and June 19, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2023.

SO WHAT: If you purchased Key securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Key class action, go to https://rosenlegal.com/submit–form/?case_id=18199 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements regarding the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) Key downplayed concerns with its liquidity while overstating the effectiveness of its long–term liquidity strategy; (2) Key overstated its projected NII for the second quarter ("Q2") and full year ("FY") of 2023, as well as related positive NII drivers, while downplaying negative NII drivers; (3) as a result, Key was likely to negatively revise its previously issued NII guidance; (4) all of the foregoing, once revealed, was likely to negatively impact Key's business, financial results, and reputation; and (5) as a result, Defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Key class action, go to https://rosenlegal.com/submit–form/?case_id=18199 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8890133)

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Arrow Financial Corporation Investors to Secure Counsel Before Important August 22 Deadline in Securities Class Action – AROW

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Arrow Financial Corporation (NASDAQ: AROW) between March 12, 2022 and May 12, 2023, both dates inclusive (the "Class Period"), of the important August 22, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Arrow securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Arrow class action, go to https://rosenlegal.com/submit–form/?case_id=17331 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 22, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Arrow maintained defective disclosure controls and procedures and internal controls over financial reporting; (2) the foregoing increased the risk that the company could not timely file one or more of its periodic financial reports with the SEC as required by the NASDAQ's listing requirements; (3) accordingly, Arrow was at an increased risk of being delisted from the NASDAQ; (4) following the disclosure of deficiencies in the Company's disclosure controls and procedures and internal controls over financial reporting, Arrow downplayed the severity of these issued and the associated risks; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Arrow class action, go to https://rosenlegal.com/submit–form/?case_id=17331 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8889852)

Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results

Mont–Saint–Guibert, Belgium "" August 8, 2023 10:05pm CET / 4:05pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2023.

Recent Financial and Operating Highlights

  • Presented 12–month efficacy data1 on the first 34 DREAM patients and safety data on all DREAM patients at SLEEP 2023, demonstrating a 65% AHI responder rate, a 76% ODI responder rate and safety in–line with expectations. These data are preliminary and not conclusive of final DREAM success.
  • Filed the second module in the modular PMA submission.
  • Accelerated U.S. pre–commercialization efforts, focused on market access and commercial leadership.
  • Continued to enroll the ACCCESS U.S. IDE pivotal study to treat complete concentric collapse (CCC) patients. Implant completion is expected in 2024.
  • Reported second–quarter sales of 1.1 million and ended the quarter with 42 active German accounts.
  • Ended the quarter with a cash position of 84.5 million, providing an anticipated cash runway into late 2024.

"Being less than nine months away from the DREAM study readout, our attention continues to be on patient follow up. We are highly encouraged by both the efficacy and safety data presented at SLEEP 2023. Our modular PMA filing is well underway, with the second module submitted during the quarter," commented Olivier Taelman, Nyxoah's Chief Executive Officer. "We are building strong commercial expertise in the competitive German market. Our direct–to–consumer advertising, helpline and referral networks have increased HGNS penetration and give us confidence on entering new markets."

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)
(in thousands)

For the three months ended June 30 For the six months ended June 30
2023 2022 2023 2022
Revenue 1,107 936 1,548 1,595
Cost of goods sold ( 419) ( 334) ( 594) ( 623)
Gross profit 688 602 954 972
Research and Development Expense (6,605) (3,470) (12,762) (7,065)
Selling, General and Administrative Expense (6,185) (4,536) (11,736) (8,729)
Other income/(expense) 219 14 265 150
Operating loss for the period (11,883) (7,390) (23,279) (14,672)
Financial income 789 4 669 1 414 6 246
Financial expense ( 775) (2 162) (1,732) (2 950)
Loss for the period before taxes (11,869) (4,883) (23,597) (11,376)
Income taxes ( 928) ( 107) (1,110) ( 315)
Loss for the period (12,797) (4,990) (24,707) (11,691)
Loss attributable to equity holders (12,797) (4,990) (24,707) (11,691)
Other comprehensive loss
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences ( 50) ( 12) ( 78) ( 114)
Total comprehensive loss for the year, net of tax (12,847) (5,002) (24,785) (11,805)
Loss attributable to equity holders (12,847) (5,002) (24,785) (11,805)
Basic Loss Per Share (in EUR) (0.447) (0.193) (0.907) (0.453)
Diluted Loss Per Share (in EUR) (0.447) (0.193) (0.907) (0.453)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited)

(in thousands)

As at
June 30
2023 		December 31 2022
ASSETS
Non–current assets
Property, plant and equipment 2,813 2,460
Intangible assets 44,488 39,972
Right of use assets 3,571 3,159
Deferred tax asset 48 47
Other long–term receivables 165 173
51,085 45,811
Current assets
Inventory 1,146 882
Trade receivables 1,820 1,463
Other receivables 2,262 1,775
Other current assets 1,576 1,284
Financial assets 67,919 76,968
Cash and cash equivalents 16,604 17,888
91,327 100,260
Total assets 142,412 146,071
EQUITY AND LIABILITIES
Capital and reserves
Capital 4,924 4,440
Share premium 246,070 228,275
Share based payment reserve 7,005 5,645
Other comprehensive income 98 176
Retained loss (142,522) (118,212)
Total equity attributable to shareholders 115,575 120,324
LIABILITIES
Non–current liabilities
Financial debt 8,433 8,189
Lease liability 2,991 2,586
Pension liability 50 '
Provisions 127 59
Deferred tax liability ' '
11,601 10,834
Current liabilities
Financial debt 559 388
Lease liability 751 719
Trade payables 4 690 4,985
Current tax liability 4 475 3,654
Other payables 4 761 5,167
15,236 14,913
Total liabilities 26,837 25,747
Total equity and liabilities 142,412 146,071

Revenue

Revenue was 1.1 million for the second quarter ending June 30, 2023, compared to 0.9 million for second quarter ending June 30, 2022.

Cost of Goods Sold

Cost of goods sold was 0.4 million for the three months ending June 30, 2023, representing a gross profit of 0.7 million, or gross margin of 62.2%. This compares to total cost of goods sold of 0.3 million in the second quarter ending June 30, 2022, for a gross profit of 0.6 million, or gross margin of 64.3%.

Research and Development Expenses

Research and development expenses were 6.6 million for the three months ending June 30, 2023, versus 3.5 million for the prior year period, driven by an acceleration in clinical activities, notably the start of the ACCCESS study.

Selling, General and Administrative Expenses

Selling, general and administrative expenses rose to 6.2 million for the second quarter of 2023, up from 4.5 million in the second quarter of 2022. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah's corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

Operating Loss

Total operating loss for the second quarter 2023 was 11.9 million versus 7.4 million in the second quarter of 2022. This was driven by the acceleration in the Company's R&D spending, as well as ongoing commercial and clinical activities.

Cash Position
As of June 30, 2023, cash and financial assets totaled 84.5 million, compared to 94.9 million on December 31, 2022. Total cash burn was approximately 4.8 million per month during the second quarter of 2023.

First Half 2023 Report
Nyxoah's financial report for the first half 2023, including details of the consolidated results, are available on the investor page of Nyxoah's website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public today at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 2023 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah's Q2 2023 earnings call. After registering, an email will be sent, including dial–in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the utility of clinical data in potentially obtaining FDA approval of the Genio system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20–F for the year ended December 31, 2022, filed with the Securities and Exchange Commission ("SEC") on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

1 For the trial to be successful, of the 115 patients, at least 63% of patients need to be AHI and ODI responders at the 12–month follow–up.

Attachment


GLOBENEWSWIRE (Distribution ID 1000833480)

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Deuxième Trimestre et Premier Semestre 2023

INFORMATIONS RGLEMENTES

Nyxoah Prsente ses Rsultats Financiers et d'Exploitation pour le Deuxime Trimestre et Premier Semestre 2023

Mont–Saint–Guibert, Belgique "" 8 Aot 2023, 22h05 CET / 16h05 ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ( Nyxoah ou la Socit ) opre dans le secteur des technologies mdicales et se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). Elle annonce aujourd'hui ses rsultats financiers et d'exploitation pour le deuxime trimestre et le premier semestre 2022.

Temps forts financiers et d'exploitation

  • Prsentation des donnes d'efficacit 12 mois sur les 34 premiers patients DREAM1 et des donnes de scurit sur tous les patients DREAM lors de SLEEP 2023, dmontrant un taux de rponse l'IAH de 65 %, un taux de rponse l'IDO de 76 % et une scurit conforme aux attentes. Ces donnes sont prliminaires et ne permettent pas de conclure au succs final de DREAM.
  • Soumission du deuxime module de la demande d'autorisation modulaire de mise sur le march (PMA).
  • Acclration des efforts de pr–commercialisation aux Etats–Unis, axs sur l'accs au march et le leadership commercial.
  • Poursuite du recrutement de l'tude pivot IDE ACCCESS aux tats–Unis pour traiter les patients atteints de collapse concentrique complet (CCC). L'achvement de la phase d'implantation est prvu pour 2024.
  • Chiffre d'affaires de 1,1 million d'euros au deuxime trimestre et 42 comptes allemands actifs la fin du trimestre.
  • A la fin du trimestre, la socit disposait d'une trsorerie de 84,5 millions d'euros, ce qui devrait permettre de disposer de liquidits jusqu'au dernier trimestre 2024.

” moins de neuf mois de la publication des rsultats de l'tude DREAM, nous continuons nous concentrer sur le suivi des patients. Nous sommes trs encourags par les donnes d'efficacit et de scurit prsentes SLEEP 2023. Notre demande modulaire d'autorisation de mise sur le march est en bonne voie, le deuxime module ayant t soumis au cours du trimestre “, a comment Olivier Taelman, CEO de Nyxoah. “Nous sommes en train d'acqurir une solide expertise commerciale sur le march concurrentiel de l'Allemagne. Notre communication directe auprs des consommateurs, notre service d'assistance tlphonique et nos rseaux de rfrence ont augment la pntration de la stimulation du nerf hypoglosse et nous donnent confiance pour pntrer de nouveaux marchs.”

COMPTE DE RESULTATS INTERMEDIAIRES CONSOLIDS NON AUDITS (en milliers)

Pour la priode de trois mois termine le 30 juin Pour la priode de six mois termine le 30 juin
2023 2022 2023 2022
Chiffre d'affaires 1,107 936 1,548 1,595
Cot des biens vendus ( 419) ( 334) ( 594) ( 623)
Bnfice brut 688 602 954 972
Frais de recherche et de dveloppement (6,605) (3,470) (12,762) (7,065)
Frais de vente, dpenses administratives et autres frais gnraux (6,185) (4,536) (11,736) (8,729)
Autres revenus / (frais) d'exploitation 219 14 265 150
Perte d'exploitation de la priode (11,883) (7,390) (23,279) (14,672)
Produits financiers 789 4 669 1 414 6 246
Charges financires ( 775) (2 162) (1,732) (2 950)
Perte de la priode avant impts (11,869) (4,883) (23,597) (11,376)
Impts sur le rsultat ( 928) ( 107) (1,110) ( 315)
Perte de la priode (12,797) (4,990) (24,707) (11,691)
Perte attribuable aux actionnaires (12,797) (4,990) (24,707) (11,691)
Autres lments du rsultat global
Elments pouvant tre reclassifis en bnfices ou en pertes (nets d'impts)
Diffrences de conversion de devises ( 50) ( 12) ( 78) ( 114)
Perte globale totale de la priode, nette d'impts (12,847) (5,002) (24,785) (11,805)
Perte attribuable aux actionnaires (12,847) (5,002) (24,785) (11,805)
Perte par action (en ) (0.447) (0.193) (0.907) (0.453)
Perte dilue par action (en ) (0.447) (0.193) (0.907) (0.453)

BILAN CONSOLID NON AUDIT (en milliers)

Au
30 juin
2023		 31 dcembre
2022
ACTIFS
Actifs non courants
Immobilisations corporelles 2,813 2,460
Immobilisations incorporelles 44,488 39,972
Droit d'utilisation des actifs 3,571 3,159
Actif d'impts diffrs 48 47
Autres crances long terme 165 173
51,085 45,811
Actifs courants
Stocks 1,146 882
Crances commerciales 1,820 1,463
Autres crances 2,262 1,775
Autres actifs courants 1,576 1,284
Actifs financiers 67,919 76,968
Trsorerie et quivalents de trsorerie 16,604 17,888
91,327 100,260
Total de l'actif 142,412 146,071
CAPITAUX PROPRES ET PASSIFS
Capital et rserves
Capital 4,924 4,440
Prime d'mission 246,070 228,275
Rserve pour paiement fond sur des actions 7,005 5,645
Autres lments du rsultat global 98 176
Rsultats reports (142,522) (118,212)
Total des capitaux propres attribuables aux actionnaires 115,575 120,324
PASSIFS
Passifs non courants
Dettes financires 8,433 8,189
Passifs locatifs 2,991 2,586
Passifs au titre des retraites 50 '
Provisions 127 59
Passif d'impts diffrs ' '
11,601 10,834
Passifs courants
Dettes financires 559 388
Passifs locatifs 751 719
Dettes commerciales 4 690 4,985
Passif d'impts exigibles 4 475 3,654
Autres dettes 4 761 5,167
15,236 14,913
Total du passif 26,837 25,747
Total des capitaux propres et du passif 142,412 146,071

Chiffre d'affaires
Le chiffre d'affaires s'est lev 1,1 million d'euros pour le deuxime trimestre se terminant le 30 juin 2023, contre 0,9 million d'euros pour le deuxime trimestre se terminant le 30 juin 2022.

Cot des marchandises vendues
Le cot des marchandises vendues s'est lev 0,4 million d'euros pour le trimestre clos le 30 juin 2023, soit une marge brute de 0,7 million d'euros, ou une marge brute de 62,2 %. titre de comparaison, le cot total des marchandises vendues tait de 0,3 million d'euros au deuxime trimestre se terminant le 30 juin 2022, soit un bnfice brut de 0,6 million d'euros, ou une marge brute de 64,3 %.

Frais de recherche et dveloppement
Les dpenses de recherche et dveloppement se sont leves 6,6 millions d'euros pour le trimestre clos le 30 juin 2023, contre 3,5 millions d'euros pour la priode de l'anne prcdente, sous l'effet d'une acclration des activits cliniques, notamment le dmarrage de l'tude ACCCESS.

Frais commerciaux, gnraux et administratifs
Les frais commerciaux, gnraux et administratifs ont augment pour atteindre 6,2 millions d'euros au deuxime trimestre 2023, contre 4,5 millions d'euros au deuxime trimestre 2022. Cela s'explique principalement par l'intensification des efforts commerciaux en Allemagne et sur d'autres marchs europens, ainsi que par des investissements dans l'infrastructure de l'entreprise Nyxoah. La socit prvoit de continuer ajouter des effectifs dans l'ensemble de l'organisation avant le lancement commercial aux tats–Unis.

Perte d'exploitation
La perte d'exploitation totale pour le deuxime trimestre 2023 s'est leve 11,9 millions d'euros contre 7,4 millions d'euros au deuxime trimestre 2022. Cette volution s'explique par l'acclration des dpenses de R&D de la Socit, ainsi que par les activits commerciales et cliniques en cours.

Position de trsorerie
Au 30 juin 2023, la trsorerie et les actifs financiers s'levaient 84,5 millions d'euros, contre 94,9 millions d'euros au 31 dcembre 2022. La consommation totale de trsorerie a t d'environ 4,8 millions d'euros par mois au cours du deuxime trimestre 2023.

Rapport du premier semestre 2022

Le rapport financier de Nyxoah pour le premier semestre 2023, y compris les dtails des rsultats consolids audits, sont disponibles sur la page investisseurs du site web de Nyxoah (https://investors.nyxoah.com/financials).

Confrence tlphonique et prsentation par webcast
La Socit organisera une confrence tlphonique ouverte au public ce jour 22h30 CET / 16h30 ET. La retransmission de la confrence tlphonique sera accessible sur la page Relations avec les investisseurs du site web de Nyxoah ou par le biais de ce lien : Nyxoah's Q2 2023 earnings call webcast. Pour ceux qui n'ont pas l'intention de poser une question au Management, la Socit recommande d'couter la webdiffusion.

Si vous avez l'intention de poser une question, veuillez utiliser le lien suivant : Nyxoah's Q2 2023 earnings call. Aprs l'inscription, un courriel sera envoy, comprenant les dtails de la composition et un code d'accs unique la confrence tlphonique ncessaire pour rejoindre l'appel en direct. Pour s'assurer que vous tes connect avant le dbut de la confrence, la Socit suggre de s'inscrire au moins 10 minutes avant le dbut de l'appel.

Le webcast archiv pourra tre rcout peu aprs la clture de la confrence.

propos de Nyxoah
Nyxoah opre dans le secteur des technologies mdicales. Elle se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le systme Genio , une thrapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reu le marquage CE, centre sur le patient et destine traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associ un risque accru de mortalit et des comorbidits, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits rparatrices et vivre pleinement leur vie.

la suite de la finalisation probante de l'tude BLAST OSA, le systme Genio a reu le marquage europen CE en 2019. Nyxoah a ralis avec succs deux IPO : l'une sur Euronext Bruxelles en septembre 2020 et l'autre sur le NASDAQ en juillet 2021. Grce aux rsultats positifs de l'tude BETTER SLEEP, Nyxoah a reu le marquage CE pour l'extension de ses indications thrapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thrapies concurrentes sont actuellement contre–indiques. En outre, la Socit mne actuellement l'tude pivot IDE DREAM pour la FDA obtenir l'autorisation de mise sur le march.

Pour de plus amples informations, veuillez consulter le site http://www.nyxoah.com/.

Attention "" marquage CE depuis 2019. Dispositif de recherche aux tats–Unis. Limit un usage exprimental aux tats–Unis par la loi fdrale amricaine.

Dclarations prospectives
Certaines dclarations, croyances et opinions contenues dans le prsent communiqu de presse sont de nature prospective et refltent les attentes actuelles de la socit ou, le cas chant, des administrateurs ou de la direction de la socit concernant le systme Genio , les tudes cliniques prvues et en cours sur le systme Genio , les avantages potentiels du systme Genio ; les objectifs de Nyxoah en ce qui concerne le dveloppement, la voie rglementaire et l'utilisation potentielle du systme Genio ; l'utilit des donnes cliniques pour l'obtention ventuelle de l'approbation du systme Genio par la FDA ; et les rsultats d'exploitation, la situation financire, les liquidits, les performances, les perspectives, la croissance et les stratgies de la socit. De par leur nature, les dclarations prvisionnelles impliquent un certain nombre de risques, d'incertitudes, d'hypothses et d'autres facteurs qui pourraient faire en sorte que les rsultats ou vnements rels diffrent matriellement de ceux exprims ou sous–entendus dans les dclarations prvisionnelles. Ces risques, incertitudes, hypothses et facteurs pourraient avoir une incidence ngative sur les rsultats et les effets financiers des plans et des vnements dcrits dans le prsent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes noncs dans la section “Facteurs de risque” du rapport annuel de la socit sur le formulaire 20–F pour l'exercice clos le 31 dcembre 2022, dpos auprs de la Securities and Exchange Commission (“SEC”) le 22 mars 2023, et des rapports ultrieurs que la socit dpose auprs de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les vnements, les performances ou les rsultats rels diffrent de manire significative de tout dveloppement anticip. Les dclarations prospectives contenues dans le prsent communiqu de presse concernant des tendances ou des activits passes ne constituent pas des garanties de performances futures et ne doivent pas tre considres comme une dclaration selon laquelle ces tendances ou activits se poursuivront l'avenir. En outre, mme si les rsultats ou dveloppements rels sont conformes aux dclarations prospectives contenues dans le prsent communiqu de presse, ces rsultats ou dveloppements peuvent ne pas tre reprsentatifs des rsultats ou dveloppements des priodes futures. Aucune dclaration ou garantie n'est donne quant l'exactitude ou la sincrit de ces dclarations prospectives. En consquence, la socit dcline expressment toute obligation ou tout engagement de publier des mises jour ou des rvisions des dclarations prospectives contenues dans le prsent communiqu de presse la suite d'un changement des attentes ou d'un changement des vnements, conditions, hypothses ou circonstances sur lesquels ces dclarations prospectives sont bases, sauf si la loi ou la rglementation l'exige expressment. Ni la Socit, ni ses conseillers ou reprsentants, ni aucune de ses filiales, ni les dirigeants ou employs de ces personnes ne garantissent que les hypothses sous–jacentes ces noncs prospectifs sont exemptes d'erreurs et n'acceptent aucune responsabilit quant l'exactitude future des noncs prospectifs contenus dans le prsent communiqu de presse ou la survenance relle des dveloppements prvus. Vous ne devriez pas accorder une confiance excessive aux dclarations prospectives, qui ne sont valables qu' la date du prsent communiqu de presse.

Contact :
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

1 Pour que l'essai soit concluant, il faut qu'au moins 63 % des 115 patients soient rpondeurs l'IAH et l'IDO lors du suivi 12 mois.

Pice jointe


GLOBENEWSWIRE (Distribution ID 1000833480)

FUTU FINAL DEADLINE FRIDAY: NATIONALLY RANKED ROSEN LAW FIRM Encourages Futu Holdings Limited Investors to Secure Counsel Before Important August 11 Deadline in Securities Class Action Filed by the Firm – FUTU

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminder purchasers of the securities of Futu Holdings Limited (NASDAQ: FUTU) between April 27, 2020 and May 16, 2023, both dates inclusive (the "Class Period"), of the important August 11, 2023 lead plaintiff deadline, in the securities class action commenced by the Firm.

SO WHAT: If you purchased Futu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Futu class action, go to https://rosenlegal.com/submit–form/?case_id=16261 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose, among other things, that: (1) Futu's business was, quite simply, illegal as it related to operations in China as a result of its failure to obtain the proper licenses; (2) it did not fully disclose to investors that it was engaging in unlawful activity and instead falsely characterized the applicable Chinese laws as ambiguous; (3) the foregoing subjected the Company to a heightened risk of regulatory enforcement; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Futu class action, go to https://rosenlegal.com/submit–form/?case_id=16261 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8889988)

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Baxter International Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BAX

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baxter International Inc. (NYSE: BAX) between May 12, 2022 and February 8, 2023, both dates inclusive (the "Class Period"), of the important September 11, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Baxter securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Baxter class action, go to https://rosenlegal.com/submit–form/?case_id=17664 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 11, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Baxter concealed the true extent of the supply chain problems it was experiencing while simultaneously exaggerating its ability to maintain a healthy supply chain in the face of global pressures; (2) as a result, Baxter's projected earnings were materially misleading during the Class Period; (3) the foregoing, once revealed, was reasonably likely to have a material negative impact on Baxter's financial condition; and (4) as a result, Baxter's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Baxter class action, go to https://rosenlegal.com/submit–form/?case_id=17664 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8889843)

LYV EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Live Nation Entertainment, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – LYV

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Live Nation Entertainment, Inc. (NYSE: LYV) between February 23, 2022 and July 28, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2023.

SO WHAT: If you purchased Live Nation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Live Nation class action, go to https://rosenlegal.com/submit–form/?case_id=18184 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements regarding the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) Live Nation engaged in anticompetitive conduct, including charging high fees and extended contracts with talent, and retaliated against venues; (2) that, as a result, Live Nation was reasonably likely to incur regulatory scrutiny and face fines, penalties, and reputational harm; and; (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Live Nation class action, go to https://rosenlegal.com/submit–form/?case_id=18184 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8889788)

Cellebrite Appoints Thomas E. Hogan as Executive Chairman of the Board

Seasoned Technology Leader to Partner with CEO Yossi Carmil to Further Company Growth and Strategic Priorities

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 08, 2023 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, announced today that proven industry veteran, Thomas E. Hogan has been appointed Executive Chairman of the Board.

Based in Austin, Texas, Hogan brings a remarkable 40+ year track record of exceptional shareholder returns, client impact, and employee growth. He has significant expertise in strategic M&A, sales and marketing, international operations, and talent acquisition and development. During his career Tom has led numerous acquisitions totally nearly $8B including marquis targets such as Mercury Interactive and Opsware. His career includes over a decade as both a private and publicly held software CEO as well as senior executive posts ranging from late stage private to mega–cap public companies.

"Tom's experience will be invaluable as we scale Cellebrite, extend our market leading digital intelligence solutions, and ultimately enable justice across the globe. I am excited to partner closely with Tom as we navigate our next chapter of growth and global impact," said Yossi Carmil, CEO, Cellebrite.

"I look forward to my new partnership with Yossi, Haim Shani and the entire Cellebrite board, and the talented men and women across Cellebrite, as we build upon the impressive momentum of the company. I am especially enthused about the mission–driven purpose of this organization and our opportunity to better equip law enforcement and judicial systems worldwide," said Thomas E. Hogan, Executive Chairman of the Board.

Hogan previously served as chairman and CEO of Kony, Inc, President and CEO of Vignette (VIGN), executive vice president of sales and marketing for Hewlett Packard, executive vice president of software for HP, executive vice president of CSC, chief sales officer at Siebel Systems, and most recently as a Operating Managing Director at Vista Equity Partners. He has held numerous public and private board positions including directorships at Citrix, Gainsight, Pluralsight, Drift, Vignette, Kony, Vastera, and Inforte. Tom holds a Masters in Management from Northwestern University and a B.S. in Biomedical Engineering from the University of Illinois.

Cellebrite's current non–executive chairman, Haim Shani, will remain an active member of the board. Haim will leverage his extensive experience as the former CEO of NICE, the former Director General of the Israel Ministry of Finance, and his current role as founder and general manager of Israel Growth Partners, to further strengthen contributions from the Cellebrite board.

"On behalf of the entire Cellebrite board, I am pleased to welcome Tom to the Cellebrite team. Getting to know Tom as the head of the search committee and working with Yossi the past four years, I believe their combined strengths deliver the best leadership team in the industry. While I am passing the torch of chairman duties to Tom, I will continue to contribute as an active member of the Cellebrite board and look forward to working closely with Tom and the Cellebrite management team as we continue our journey," said Haim Shani, former Cellebrite chairman.

About Cellebrite

Cellebrite's (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes.

Trusted by thousands of leading agencies and companies worldwide, Cellebrite's Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Caution Regarding Forward–Looking Statements

This document includes "forward–looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward–looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "could," "continue," "expect," "estimate," "may," "plan," "outlook," "future" and "project" and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward–looking statements include estimated financial information. Such forward–looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of the business of Cellebrite are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward–looking statements. These factors include, but are not limited to: Cellebrite's ability to develop technologically advanced solutions and successfully integrate with the software solutions used by customers; acceptance of solutions by customers; errors, failures, defects or bugs in solutions; a failure to maintain sales and marketing personnel productivity or hire, integrate and retain additional sales and marketing personnel; the impact of the global COVID–19 pandemic; the impact of competition on pricing and on Cellebrite's market share; sub–optimal results from products due to misuse by customers; Cellebrite's failure to maintain and enhance its reputation and brand; inaccuracy of the estimates of Cellebrite's market opportunity and forecasts of market growth; changes to packaging and licensing models that adversely affect the ability to attract or retain customers; failure to manage future growth effectively; failure to introduce new solutions and add–ons; issues in the use of artificial intelligence resulting in reputational harm or liability; the need for additional capital to support the growth of Cellebrite's business; a failure to maintain the security of operations and the integrity of software solutions; the impact of government budgeting cycles and appropriations, early termination, audits, investigations, sanctions and penalties; a decline in government budgets, changes in spending or budgetary priorities, or delays in contract awards; a failure to adequately obtain, maintain, protect and enforce Cellebrite's intellectual property or infringement of the intellectual property rights of others; perceptions or court or regulatory decisions that Cellebrite's solutions violate privacy rights; the use of solutions by customers in a way that is, or that is perceived to be, incompatible with human rights; failure to comply with laws regarding privacy, data protection and security, technology protection, sanctions, export controls and other matters; and other factors, risks and uncertainties set forth in the sections titled "Risk Factors" and "Cautionary Note Regarding Forward–Looking Statements" in our Annual Report on form 20–F filed with the SEC on March 29, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ("SEC"), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward–looking statements, whether as a result of new information, future developments, or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Cellebrite Contacts

Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910

Investors
Andrew Kramer
VP, Investor Relations
Investors@cellebrite.com
+1 973.206.7760

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/774b7b9d–8b12–4bd0–9ff6–ad1b46feb3e0


GLOBENEWSWIRE (Distribution ID 8889189)

Empowering Women in Assam: Livestock Farming Brings Economic Relief Post-COVID

Goat rearing is contributing to economic independence and improved livelihoods of women thanks to a post-COVID-19 empowerment project. CREDIT: Umar Manzoor Shah/IPS

Goat rearing is contributing to economic independence and improved livelihoods of women thanks to a post-COVID-19 empowerment project. CREDIT: Umar Manzoor Shah/IPS

By Umar Manzoor Shah
MILONPUR, INDIA, Aug 8 2023 – Seema Devi is a 39-year-old woman hailing from India’s northeastern state of Assam. She lives in a village called Milonpur, a small hamlet with no more than 1 000 inhabitants. While most men from the village, including Devi’s husband, move to cities and towns in search of work, women are left behind to take care of the house and kids.

Devi says that after the COVID-19 lockdown in India in the year 2020, the family income drastically plummeted. As most of the factories were shut for months, the workers, including Devi’s husband, were jobless. Even after the lockdown ended and workers were called back to the factories, the wages dipped.

“Earlier my husband would earn no less than Rs 10 000 a month (125 USD), and after the lockdown, it wasn’t more than a mere 6 000 rupees (70 USD). My children and I would suffer for the want of basic needs like medicine and clothing, but at the same time, I was considerate of the situation and helplessness of my husband,” Devi told IPS.

However, there were few alternatives available at home that could have mitigated Devi’s predicament. With the small area of ancestral land used for cultivation, the change in weather patterns caused her family and several households in the village to reap losses.

However, in 2021, a non-government organization visited the hamlet to assess the situation in the post-COVID scenario. The villagers told the team about how most of the men in the village go out to cities and towns in search of livelihood and work as labourers in factories and that their wages have come down due to economic distress in the country.

After hectic deliberations, about ten self-help groups of women were created. They trained in livestock farming and how this venture could be turned into a profitable business.

The women were initially reluctant because they were unaware of how to make livestock farming profitable. They would ask the members of the charitable organisation questions like, “What if it fails to yield desired results? What if some terrible disease affects the animals, and what if the livestock wouldn’t generate any income for them?”

Wilson Kandulna, who was the senior member of the team, told IPS that experts were called in to train the women about cattle rearing and how timely vaccinations, proper feed, and care could make livestock farming profitable and mitigate their basic living costs. “At first, we provided ten goat kids to each women’s group and made them aware of the dos and don’ts of this kind of farming. They were quick to learn and grasped easily whatever was taught to them,” Wilson said.

He added that these women were living in economic distress due to the limited income of their husbands and were desperately anxious about the scarcity of proper education for children and other daily needs.

Devi says that as soon as she got the goat kids, she acquired basic training in feeding them properly and taking them for vaccinations to the nearby government veterinary hospital.

“Two years have passed, and now we have hundreds of goats as they reproduce quickly, and we are now able to earn a good income. During the first few months, there were issues like feeding problems, proper shelter during monsoons and summers, and how and when we should take them out for grazing. As time passed and we learned the skills, we have become very trained goat rearers,” Devi said.

Renuka, another woman in the self-help group, told IPS that for the past year, they have been continuously getting demands for goat milk from the main towns. “People know about the health benefits of goat milk. They know it is organic without any preservatives, and that is the reason we have a very high demand for it. We sell it at a good price, and at times, demand surpasses the supply,” Renuka said.

For Devi, livestock farming has been no less than a blessing. She says she earns more than five thousand rupees a month (about 60 USD) and has been able to cover daily household expenses all by herself. “I no longer rely on my husband for household expenses. I take care of it all by myself. My husband, too, is relieved, and things are getting back on track,” Devi said, smiling.

Kalpana, a 32-year-old member of the group, says the goats have increased in number, and last year, several of them were sold in the market at a good price.

“The profits were shared by the group members. Earlier, women in this village were entirely dependent on their husbands for covering their basic expenses. Now, they are economically self-reliant. They take good care of the house and of themselves,” Kalpana told IPS News.

Note: Names of some of the women have been changed on their request.

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

A Flawed GDP Bypasses Women’s Unpaid Care Work

From street vendors and domestic workers to subsistence farmers and seasonal agriculture workers, women make up a disproportionate percentage of workers in the informal sector. In South Asia, over 80 per cent of women in non-agricultural jobs are in informal employment; in sub-Saharan Africa, 74 per cent; and in Latin America and the Caribbean, 54 percent. Credit: UN Women

By Naila Kabeer
LONDON, Aug 8 2023 – Last week the IMF offered a cautious estimate of positive global economic growth for this year, warning ‘we are on track, but not out of the woods’. But with the IMF and governments continuing to use gross domestic product (GDP) as the dominant measure of economic progress, a more appropriate warning might be that ‘we’ are failing to see the wood for the trees.

As multiple crises wreak havoc across the world, as inequality continues to rise inexorably, as we approach near irreversible climate breakdown, it strains credulity that governments remain fixated on a metric that is incapable of capturing these momentous changes and their profound consequences for our lives.

GDP was developed to measure the monetary value of the marketed goods and services produced in an economy but it rapidly became the predominant measure of national welfare. As such it is flawed.

We should recall the warning issued by Simon Kuznets, founding father of GDP, back in 1934: the welfare of a nation could not, and should not, be inferred from the measurement of its GDP.

GDP is blind to the distribution of the marketed goods and services it measures; it equates progress with growing wealth, even if that wealth is concentrated among a small minority of the world’s population.

It fails to distinguish between market activities that harm people and planet and those that are beneficial. It ignores the value of unpaid care. And it only recognizes natural resources when they can be exploited for profit.

Credit: UN Women/Zhanarbek Amankulov

As the feminist economist Marilyn Waring put it, GDP embodies an economic system that counts oil spills and wars as positive contributions to growth but deems the unpaid care of children and families as valueless.

Take the example of unpaid care work, overwhelmingly carried out by women across the world. According to data cited in an Oxfam paper this week, almost two-thirds of women’s weekly working hours – and forty-five percent of the total for all adults – do not enter estimates of GDP because they do not enter the market.

That means nearly 90 billion hours of unpaid care work, without which economic growth would come to a grinding halt, do not count as part of that growth!

History has shown us that fixation on GDP-oriented growth has led to government policies that directly harm women, particularly those at the intersection of multiple inequalities, such as race, class, caste and disability.

This is evident in the consequences of repeated and sustained austerity cuts to public services, here in the UK and elsewhere, including many countries in the Global South. These showed up clearly in the UK during the pandemic.

Cuts in welfare services on which many women depended in order to take up paid work meant that they had to compensate with increased unpaid labour. Cuts to jobs and pay in the public sector where women workers made up most of the work force meant higher rates of female unemployment.

And where public services were retained, as in the health sector, women from poor and minority households made up the majority of frontline workers, were those most exposed to infection.

There are alternative measures of wellbeing to GDP. Some are based on indigenous conceptualizations that stress harmony between people and planet. Others seek to build on common values found across the world: values that stress care and capabilities, culture and leisure, connections with nature and community and, very importantly, democratic participation and social justice.

What these measures all have in common is that GDP is no longer considered the primary goal of national efforts but just one of the means by which shared goals can be achieved.

This proliferation of concepts is indicative of the deep dissatisfaction with GDP on the part of many and the need to go beyond it. They include international organizations like the UN, the OECD and the EU, governments like New Zealand, Canada, Bhutan, Peru, Ecuador as well as numerous networks of activists and academics.

The fact that they have not arrived at an agreed alternative to GDP reflects at least two major challenges. The first is methodological but one that can be resolved through debate and deliberation. Do we want a single, multidimensional index to track how we are doing, more complex than GDP but closer to shared values?

Or should we opt for a dashboard of indicators that allow us to track where we are doing well and where we are falling behind? Should the alternative be nationally determined or internationally?

One argument in favour of an internationalist consensus is the need to factor in ‘the wellbeing elsewhere’ dimension: what we do within one country can have positive or negative repercussions for people in other countries.

The second challenge is political and harder to resolve, as economic elites have been able to capture political power. The richest 1% are not just the wealthiest, they have greatest political clout. They also have strong vested interest in defending a measure of progress that ensures they can legitimately capture the bulk of the wealth generated by markets.

Conversely, those who have most to gain from alternative measures of progress are dispersed and divided – in no small way through the efforts of the 1%. The second challenge therefore is to find a bridge across these divisions and dispersions so that we can collectively engage in the task of revolutionizing the way we think about ourselves in relation to each other and to our planet.

Professor Naila Kabeer is a feminist economist, Department of International Development, London School of Economics (LSE).

https://www.lse.ac.uk/international-development/people/naila-kabeer

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);